Michael Morris, MD, Prostate Cancer Section Head, GU Oncology, Memorial Sloan Kettering Cancer Center, was interviewed by Akhil Saji, MD, urology resident at New York Medical College/Westchester Medical Center on the future of PSMA-targeted therapies in APC.
- Michael Morris, MD Discusses the Future of PSMA-Targeted Therapies in APC - Part 2 ( Download)
- Michael Morris, MD Discusses the Future of PSMA-Targeted Therapies in APC - Part 1 ( Download)
- Michael Morris on the Future of mHSPC Treatment ( Download)
- Dr. Morris of Impact of PSMA-Targeted Imaging on Clinical Management of Prostate Cancer ( Download)
- VISION trial supports LuPSMA-targeting therapy for mCRPC | Michael Morris ( Download)
- Dr. Morris on Next Steps for PSMA–Targeted PET Imaging in Prostate Cancer ( Download)
- Dr. Morris on the Design of the Phase 3 CONDOR Trials in Recurrent Prostate Cancer ( Download)
- PSMA Targeted Therapies and the Role of the Urologist ( Download)
- Dr. Morris Discusses Biomarkers in Prostate Cancer ( Download)
- Dr. Morris on Deciding Among PET Tracers in Prostate Cancer ( Download)
- Lu-PSMA-617 deployment and future of prostate cancer treatment ( Download)
- Role of Medical Oncologists in prostate cancer management ( Download)
- Phase1b Trial Investigates Atezolizumab and Radium-223 in mCRPC ( Download)
- 10/3/2019 - Session 2: Michael J. Morris, MD ( Download)
- Dr. Morris on rPFS as an Endpoint in Prostate Cancer Trials ( Download)
